Presentations 2014



European Public Health Association, Glasgow, Scotland, UK, 19-22 November 2014

Oral Presentations

1 A clinically useful risk-score for chronic kidney disease (CKD) in HIV infection. Amanda Mocroft on behalf of the D:A:D Study group. oral

2 Lack of Association between Use of  Efavirenz and Death from Suicide: D:A:D Study. C. Smith on behalf of the D:A:D Study Group. oral

3 Gender Differences in the Use of Cardiovascular Disease-related Interventions Among HIV-Positive persons: D:A:D Study. Camilla Ingrid Hatleberg on behalf of the D:A:D Study Grouporal

Predictive value of Prostate Specific Antigen for prostate cancer: a nested case control study in EuroSIDA. Leah Shepherd on behalf of EuroSIDA in EuroCoord oral

5 Regional differences in self-reported HIV care and management in the EuroSIDA study. Kamilla Laut on behalf of EuroSIDA in EuroCoord. oral

HIV Drug Therapy Glasgow 2014, 2nd-6th November 2014

Poster Presentations

1 Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. Jeffrey Lazarus on behalf of WHO. poster 

2 Detection of Resistance Mutations and CD4 Slopes in Individuals Experiencing Sustained Virological Failure. Anna Schultze on behalf of EuroSIDA in EuroCoord. poster

3 The prevalence and predictive value of dipstick protein (DUP) in HIV-positive persons in Europe. Amanda Mocroft on behalf of EuroSIDA EuroCoord. poster

4 Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. Maria Casadellà Fontdevila on behalf of EuroSIDA EuroCoord. poster

5 Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. Josep M Libre on behalf of EuroSIDA EuroCoord.  poster

HepHIV 2014 Conference: HIV and Viral Hepatitis: Challenges of Timely Testing and Care, Barcelona, Spain, 5-7 October 2014

Oral presentations

1 Regional differences in hepatitis testing, vaccination and treatment in the EuroSIDA study.
Jeffrey Lazarus on behalf of EuroSIDA. oral presentation,  poster


European Society of Intensive Care Medicine (ESICM) 27th Annual Congress, Barcelona, 27th September - 1st October 2014

Oral presentations


5th International Hypothermia Symposium, Edinburgh, UK, 7th-10th September 2014

Oral presentation

1 Mild Induced Hypothermia: Effects On Sepsis-Related Coagulopathy - Results From A Randomized Controlled Trial.
M. E. Johansen on behalf of CHIP/the Cooling And Surviving Septic shock trial group (CASS group), Copenhagen, Denmark.

2 Update on evidence in sepsis/encephalopathy. 

World Transplant Congress 2014 San Francisco,  26th–31st July 2014
Post-Transplant MELD Score Predicts Mortality and Re-Transplantation Among Liver Transplant Recipients. Presented by Andreas Rostved Presentation

20th International AIDS conference, Melbourne Australia, 20th - 25th 2014

 Impact of short-term change in body mass index after antiretroviral therapy initiation on subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study. A Achhra et al. Presentation

American Thoracic Society (ATS) annual meeting, San Diego, CA, USA, 16th - 21st May 2014

Oral presentation


1 The Cooling And Surviving Septic shock study (CASS) in: Time 0 – 6 hours – revisiting the Golden Hours. J.U.S. Jensen on behalf of CHIP/ the Cooling And Surviving Septic shock trial group (CASS group), Copenhagen, Denmark. presentation


21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston

Oral presentations 

1 HIV transmission risk through condomless sex if the HIV positive partner is on suppressive ART: PARTNER study A Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, V Estrada, J Van Lunzen, GM Corbelli, AM Geretti, D Asboe, P Viciano, F Gutiérrez, C Pradier, K Westling, R Weber, H Furrer, J Prins, J Gerstoft, A Phillips and J Lundgren for the PARTNER Study Group.
Q & A


Poster presentations 

1 Association Between Dideoxynucleoside Analogues (d-drugs) and End-Stage Liver Disease (ESLD). Lene Ryom on behalf of DAD

2 Predictors of Progression, Stabilisation or Improvement of eGFR After Chronic Renal Impairment. Lene Ryom on behalf of D:A:D

3 Is there continued evidence for an association between abacavir and myocardial infarction risk? Caroline Sabin on behalf of D:A:D

4 Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals. Daniel Grint on behalf of EuroSIDA